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Abbreviat io n
5-HT:  5-hydroxytrypta mine,  Serotonin
5-HT 1F : 5-hydroxytrypta mine  1F
AMPA:  α-amino- 3-hydroxy- 5-methyl- 4- isoazolepropionic  acid
CGRP:  calcitonin  gene- related  peptide
CGRP- RAs:  calcitonin  gene- related  peptide  recepto r  antagonis t s
CLR:  calcitonin  recepto r- like  recep to r
CSD:  cortical  spreading  depres sion
GPCR:  G-protein- coupled  recepto r
iGluRs:  ionotropic  glutam a t e  recep to r s
KYNA: kynurenic  acid
LC:  locus  coeruleus
L-KYN:  L-kynurenine
NMDA:  N-methyl- D-aspar t a t e
NRM:  nucleus  raphe  magnus
NTG:  nitroglycerin
PAC1:  pituita ry  adenyla te  cyclase- activating  polypep tide  type  1
PACAP:  pituita ry  adenyla te  cyclase- activating  polypep tide
PAG:  periaque d u c t a l  grey  matte r
RAMP1:  recepto r  activity  modifying  protein  1
SpC5:  spinal  trigeminal  nucleus
Tmax : time  to  maximum  concen t r a t ion
TNC:  trigeminal  nucleus  caudalis
TRIG:  trigeminal  ganglion
TS:  trigeminovascula r  system
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VIP:  vasoactive  intes tinal  peptide
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Abstrac t
Introd u c t i o n:  Migraine  is  a  common,  paroxysmal,  disabling  primary
headach e  with   a  high  personal  and  socio- economic  impact .  It  involves
approximat ely  16%  of  the  genera l  popula tion.  During  the  years,  a  number
of  hypothese s  have  been  put  forward  concerning  the  exact
pathomec h a ni s m,  but  the  final  solution  is  still  undiscovered .
Areas  cover e d:  Although  the  origin  is  enigma tic ,  parallel  therape u t ic
efforts  have  been  developed.  Curren t  attack  therapy  does  not  meet  the
expecta t ions  of  the  patient s  or  the  doctors.  This  article,  based  on  a
PubMed  search,  reviews  the  novel  pharm a cological  possibilities  that
influence  the  periphe ra l  and  cent ral  sensitiza tion  involved  in  the  disease .
Expert  opinio n:  In  order  to  overcome  the  therap eu t ic  insufficiency,  a
CGRP  recep to r  antagonis t  without  the  side- effect  of  liver  transa mina s e
elevation  is  required .  Another  therape u t ic  option  is  to  develop  a  neurally
acting  anti- migraine  agent ,  such  as  a  serotonin- 1F  recep to r  agonist ,  with
low  adverse  central  nervous  system  events.  Developme n t  of  a  potent
dopamine  recep to r  antagonis t  is  necessa ry  to  diminish  the  premoni to ry
symptoms  of  migraine .  A  furthe r  option  is  to  decreas e  the  headache
intensi ty  with  a  PAC1  recep to r  blocker  which  can  cross  the  blood- brain
barrie r .  Finally,  synthe t ic  kynurenine  analogues  are  required  to  block  the
pain  transmission  in  the  activated  trigeminal  system.
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1.  Introd u c t i o n
Migraine  is  a  devast a t ing  neurovascula r  disorde r  with  a  high  socio-
economic  and  personal  impact .  It  is  charac t e r ized  by  episodic  attacks  of
throbbing  and  pulsa ting  headach e  associa ted  with  nausea ,  vomiting,
photo-  and  phonophobia ,  cephalic  and  extraceph a lic  allodynia  and
vertigo.  It  is  a  very  common  disorde r ,  afflicting  nearly  16%  of  the  adult
popula tion  .  Despite  the  curren tly  recom m e n d e d  guidelines  concerning
the  trea tm e n t  of  an  acute  migraine  attack,  with  analgesics,  antiemet ics ,
ergot  alkaloids  and  triptans ,  many  migraineu r s  fail  to  respond  optimally.
The  majority  of  the  trea t ed  patient s  do  not  attain  a  pain-  free  status
within  2  h  after  taking  the  medica t ion,  or  the  headach e  recurs  within  24  h
.  The  aim  of  this  review  is  to  discuss  promising  pharm acological
trea tm e n t s  of  migraine  attacks,  focusing  on  calcitonin  gene- related
peptide  (CGRP)  recepto r  antagonis t s ,  5-hydroxytryp ta mine  1F  (5-HT 1F )
recepto r  agonis,  dopamine  recep to r  antagonis,  and  possible  pharm acons
that  act  on  the  pituita ry  adenylat e  cyclase- activating  polypeptide  type  1
(PAC1)  and  N-methyl- D-aspar t a t e  (NMDA)  recep to rs .
2.  Calci to n i n  gen e - relat e d  pept id e  rece pt or  antag o n i s t s  (CGRP-
RAs)
CGRP  is  a  37- amino  acid  neurope p t ide  derived  from  the  calcitonin  gene,
located  on  chromosom e  11,  that  belongs  in  the  calcitonin  gene  peptide
superfamily  .  In  humans ,  CGRP  has  two  isoforms  ( -  and  - CGRP)  whichα β
differ  in  the  amino  acids  located  at  positions  3,  22  and  25  .  It  is  a  potent
vasoactive  neuropep t ide  that  plays  an  import an t  role  in  the
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pathomec h a ni s m  of  migraine  headache ,  especially  in  the
trigeminovascula r  system  (TS).  A classical  study  elegan t ly  demons t r a t e d
an  elevated  concen t r a t ion  of  CGRP  in  the  cranial  outflow  in  the  jugular
vein  during  a  migraine  attack  .  Numerous  (up  to  50%)  CGRP-
immunore a c t ive  neurons  are  to  be  found  in  the  trigeminal  ganglion
(TRIG)  .  The  intravenous  administ r a t ion  of  CGRP  proved  to  cause
migraine- like  attacks  in  migraine  subject s  ,  and  in  migraine  attacks
provoked  by  sublingual  glyceryl  trinitr a t e ,  increas ed  CGRP
concen t r a t ions  were  observed,  which  normalized  after  the  cessa tion  of
the  migraine  .  The  anatomical  structu r e  of  the  TS  contains  the
pseudounipola r  neurons  in  the  TRIG,  the  pial  and  dural  vascula tu r e  and
the  second- order  nociceptive  neurons  in  the  trigeminal  nucleus  caudalis
(TNC)  .  The  periphe ra l  branch  of  the  pseudounipola r  neurons  innervat e s
the  vessel  wall  of  the  pial  and  dural  vascula tu r e ,  and  the  central  nerve
ending  synapse  in  the  second- order  neurons  in  the  TNC  .  During
activation  of  the  TS,  as  in  a  migraine  attack,   CGRP  is  released  from  both
the  periphe ra l  and  the  central  arch  of  the  trigeminal  neurons,  and  causes
periphe r a l  and  cent ral  sensi tiza tion  .  The  periphe r a l  sensitiza t ion
explains  the  throbbing  natu re  of  the  headache  and  the  worsening  of  the
headach e  pain  due  to  intrac r a nial  hypersens i tivity  during  physical  activity
.  The  conseque n c e s  of  central  sensitiza tion  include  cephalic  cutaneous
allodynia  and  extrac r a nial  tende rn e s s   (Figure  1).
The  recepto r  for  CGRP  has  been  identified  as  a  G-protein- coupled
recepto r  (GPCR)  of  the  family  B  - subtype  .  It  consis ts  of  three  proteins:
the  7- trans m e m b r a n e  spanning  protein  of   the  calcitonin  recepto r- like
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recepto r  (CLR),  which  forms  the  ligand- binding  site  with  the  single-
transm e m b r a n e  spanning  protein  of  recepto r  activity  modifying  protein  1
(RAMP1),  which  dete rmine s  the  specificity  and  species- selec tivity  of  the
recepto r  ,  and  the  CGRP- recepto r  componen t  protein  (RCP)  couples  the
recepto r  to  intracellula r  signal- transduc tion  pathways  via  the  CLR  and  to
adenylyl  cyclase  .
The  CGRP  recep to r  antagonis ts  were  developed  to  block  the  CGRP-
induced  vasodilation  in  the  meninges  and  the  pain  transmission  in  the
TNC  without  causing  vasocons t r ic tion.  
2.1.  Olceg e p a n t  (BIBN 4 0 9 6 B S )
BIBN4096BS,  [R-(R*,S*)]-N -[2- [[5- amino- 1-[[4- (4-pyridinyl)- 1-
piperazinyl]carbonyl]pen tyl]amino]- 1- [(3,5- dibromo- 4-
hydroxyphe nyl)met hyl]- 2-oxoethyl]-  4-  (1,4-  dihydro- 2-oxo- 3(2 H )-
quinazolinyl)-  1-piperidineca r boxa mide ,  was  the  first  selective  small
molecule  (K i=0.010  nM)  non- peptide  CGRP- RA.  Doods  et  al.
demons t r a t e d  its  pharm acological  profile  in  in  vitro  experime n t s  on  SK-N-
MC  (a  human  neuroblas tom a  cell  line)  cell  membra n e s  .  The  main
charac t e r i s t ic  of  the  CGRP  recep to r  expresse d  in  the  SK-N-MC  cell  line
was  similar  to  that  of  the  cloned  human  CGRP1  recepto r  .  BIBN4096BS
exhibited  high  affinity  for  the  human  CGRP  recepto r  (150- fold  higher  than
its  antagonis t  CGRP(8- 37))  and  strongly  inhibited  neurogenic  vasodilation
.  Because  of  its  relatively  high  molecula r  weight  (Mw =8 70)  and  low
bioavailability,  it  can  be  adminis te r e d  only  intravenously  .  The
pharm acokine t ic  profile  revealed  a  dose- propor tional  mean  maximum
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concen t r a t ion ,  resulting  in  a  terminal  half- life  (T 1/2 )  of  ~  2.5  hours.  The
mean  renal  clearanc e  was  approximat ely  2  l/h  .  It  proved  efficacious  in
the  trea tm e n t  of  acute  migraine  attacks,  with  a  low  adverse  event
profile  .  The  only  disadvan ta g e  was  the  need  for  intravenous
adminis t ra t ion,  which  impeded  its  wide- spread  clinical  use  (Table  1).  
2.2.  Telca g e p a n t  (MK- 097 4 )
For  oral  adminis t r a t ion,  a  new  CGRP- RA,  telcagep a n t  (MK-0974:  N -
[(3 R ,6 S )-6- (2,3- difluorophe nyl)hexahydro- 2-oxo- 1-(2,2,2- trifluoroe thyl)-
1 H -azepin- 3-yl]-4- (2,3- dihydro- 2-oxo- 1 H -imidazo[4,5- b]pyridin- 1-yl)-1-
piperidineca r boxa mide ),  was  synthet ized  .  On  human  CGRP- Rs,  this  is  a
poten t  antagonis t ,  with  K i=0.77  nM  .  Its  bioavailability  in  dogs  was  35%,
and  the  clearanc e  was  17  ml/min/kg,  while  in  rats  the  bioavailability  was
20%  and  the  clearanc e  was  9.4  l/min/kg  .  The  time  to  maximum
concen t r a t ion  (Tmax ) was  1.5  h  and  T1/2  was  ~  6  h  .
A Phase  II  proof- of-concep t  study  indicated  that  telcagep a n t  was  effective
versus  placebo  during  the  acute  trea tm e n t  of  migraine  and  had  a  similar
effect  to  that  of  triptan  (zolmitrip tan)  . 
Despite  its  strong  clinical  effect  in  termina ting  migraine  headache ,  the
high  incidence  of  liver  toxicity  (elevation  of  liver  transa mina s e s)  during
its  long- term  and  frequen t  use  preven ted  its  wide- clinical  utilization.
3.  5- Hydroxytrypta m i n e  1F  (5- HT 1F )  recep t or  agoni s t
Serotonin  (5-hydroxytrypta mine ,  5-HT)  was  first  isolated  from  serum  in
the  late  '40s  . Its  role  in  migraine  has  been  subst an t ia t ed  since  the  1960s.
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In  1961,  Sicute ri  et  al.  demonst r a t e d  the  enhance d  urinary  level  of  5-
hydroxyindoleac e t ic  acid  (5-HIAA)  during  migraine  attacks  ,  and
decreas e d  plasma  5-HT  level  was  also  demons t r a t e d  during  headache .
The  intravenous  adminis t r a t ion  of  5-HT  effectively  alleviated  migraine
headach es ,  though  with  a  wide  range  of  side- effects .  
The  5-HT  recepto rs  have  been  classified  into  seven  major  classes  (5-HT1
to  5-HT7).  Only  the  5-HT1B,  1D,  1F  and  2B  recepto r  subtypes  are
involved  in  pain  trans mission.  The  discovery  of  triptans  (selective  5-
HT1B/1D  recepto r  agonis ts)  more  than  20  years  ago  furnished  very
poten t  acute  anti- migraine  agents  with  selec tive  pharm acology  and
consis ten t  pharm acokine t ics  .  The  5-HT1B  recepto r  is  located  on  the
vascular  smooth  muscle,  while  5-HT1D  is  expresse d  in  the  neuronal
element  of  the  TRIG  .  The  main  mechanis m  is  based  on  cranial
vasocons t r ic tion,  periphe ra l  neuronal  inhibition  and  blocking  of  the  firing
of  nociceptive  second- order  neurons  in  the  TNC.  In  conseque nc e  of  5-
HT1B  recepto r  agonism,  they  have  the  risk  of  causing  corona ry
vasocons t r ic tion  and  chest  discomfor t  ,  which  limit  their  use  in  daily
practice.  
To  avoid  the  5-HT1B  recep to r- media ted  direct  vasocons t r ic to r  effect,  5-
HT1F  recepto r  agonis ts  have  been  synthe t ized,  as  the  5-HT1F  recepto r
does  not  affect  the  diamete r  or  contrac t ili ty  of  the  blood  vessels  .  The  5-
HT1F  recep to r  is  located  on  the  glutama t e r g ic  neurons  within  the  TRIG  .
It  has  also  been  identified  in  the  guinea  pig  hippocam p us ,  cortex,
claust ru m  and  spinal  trigeminal  nucleus  (SpC5)  ,  and  in  the  porcine
cortex,  TRIG  and  several  blood  vessels  .
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3.1.  Lasmid i ta n  (COL- 144 ,  LY573 1 4 4 )
Lasmiditan  (2,4,6- trifluoro- N -[6- [(1- methylpipe ridin- 4-yl)carbonyl]pyridin-
2yl]benzamide)  is  a  highly  selective  5-HT1F  recepto r  agonis t  available
from  Eli  Lilly.  It  does  not  contain  the  indole  core,  which  defines  the
triptans  and  the  first- genera t ion  5-HT1F  recepto r  agonist  LY334370.  An
in  vitro  binding  study  showed  its  excellent  selectivity  (470- fold)  for  5-
HT1F  recepto r s  (K i=2.21  nM)  as  compare d  with  K i values  of  1043  and
1357  nM  for  5-HT1B  and  5-HT1D,  and  its  functional  activity  in  vitro  was
proved  by  Nelson  et  al.  .  The  lack  of  a  contrac t ive  effect  of  lasmiditan  on
rabbit  saphenous  vein  rings  was  observed  up  to  a  concen t r a t ion  of  100
M.  Lasmiditan  blocked  trigeminal  stimula t ion- induced  dural  plasmaμ
protein  extravasa t ion  with  an  ID 50  of  2  x  10 -4  g/kg,  and  decreas e d  theμ
number  of  c-fos-  positive  cells  in  the  SpC5  at  a  dose  of  3  mg/kg  1  h  after
oral  adminis t r a t ion  . Thus,  in  view  of  its  new  site  of  action,  it  is  a  neurally
acting  anti- migraine  agent .
The  oral  bioavailabili ty  of  lasmiditan  is  40%,  and  its  T max  is  2  h  (CoLucid
Pharm a ce u t ical s)  .  During  a  randomized  proof- of-concept  and  dose-
finding  study,  130  subjects  were  trea te d  with  lasmiditan  intravenously  .
The  dose  range  was  2.5  mg  to  45  mg.  The  resul ts  revealed  a  linear
associa tion  between  the  response  rates  and  dose  levels.  The  effective
intravenous  dose  was  20  mg  or  more  .  In  a  Phase  II  randomized,  placebo-
controlled,  parallel- group,  dose- ranging  study,  the  efficacy  of  orally
adminis te r e d  lasmiditan  in  a  dose  of  100  mg,  or  400  mg  (64- 65%)  was
bette r  than  that  of  placebo  (26%).  The  placebo- subt rac t e d  adverse  events
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rate  was  50%  (95%  CI:  37- 63%)  for  100  mg  oral  lasmiditan ,  and  66%
(95%  CI:  50- 75%)  for  400  mg  .  Even  though  this  selective  5-HT1F
recepto r  agonist  has  a  high  incidence  of  modera t e  or  severe  adverse
centra l  nervous  system- related  events,  such  as  dizziness ,  fatigue,  vertigo
and  paraes th e s ia ,  it  is  an  alterna t ive  means  of  trea tm e n t  for  migraineu r s
who  have  contraindica t ions  for  vasocons t r ic to r  agents,  such  as  triptans  . 
4.   Dopa mi n e  recep t or  anta g o n i s t s
With  regard  to  the  occurre nc e  of  nausea ,  vomiting  and  blood  pressu re
changes  during  migraine  attacks ,  Sicute r i  proposed  possible
dopamine r gic  activation  in  migraine  .  Although  this  theory  has  not  been
substan t ia t e d  during  the  years,  some  recen t  resul ts  sugges t e d  that
dopamine  may  be  involved  in  the  pathogen es i s  of  migraine .
Dopamine  is  one  of  the  three  natu ra lly- occurr ing  catechola mines .
Dopamine  recep to r s  belong  in  the  group  of  G  protein- coupled  recepto rs .
On  the  basis  of  their  structu r a l  and  pharm acological  proper t ies ,  the
dopamine  recepto r s  are  divided  into  the  D1-  and  D2- like  family  recep to rs .
The  D1- like  family  recep to rs  (D1  and  D5)  activate  adenylyl  cyclase  and
conseque n t ly  increas e  the  intracellula r  concen t r a t ion  of  cAMP,  while
activation  of  the  D2- like  family  recepto r s  (D2,  D3  and  D4)  inhibits  the
formation  of  cAMP  .
The  findings  that  adminis t r a t ion  of  the  dopamine  agonis t  apomorphin
enhance d  nausea ,  vomiting  and  yawning,  and  that  the  platele t  levels  of
dopamine  were  increase d  in  migraine  suppor t e d  the  theory  of
hypersensi tivity  to  dopamine  in  migraineu r s  .
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D1  and  D2  dopamine  recepto rs  can  be  found  in  the  rat  TRIG,
mesence p h a lic  trigeminal  nucleus  and  trigeminoce rvical  complex  ,  which
links  dopamine  to  the  TS.  
Molecula r  genetic  studies  have  revealed  an  increase  in  the  polymorphism
of  the  DRD2  encoding  Nocardia  corallina- 1  (Nco1)  gene   and  DRD4
polymorphism   in  migraine  without  aura.  A decreas e d  allelic  distribution
of  dopamine- -hydroxylase  polymorphism  was  also  observed,β
accompanied  by  an  increase d  dopamine  level  in  migraineu r s  . 
4.1.  Proch l orp er a z i n e
The  intravenous  adminis t r a t ion  (5  to  10  mg)  of  prochlorpe r azine  led  to  a
respons e  rate  of  88%,  as  compare d  with  45%  for  placebo.  The  headach e
relief  dura t ion  was  30  min  .  Oral  doses  of  5  or  10  mg,  and  supposi tories
of  25  mg  were  useful.  A long  QTc  interval  is  a  contraindica t ion.  The  most
common  adverse  events  are  akathisia ,  sedat ion  and  tachycardia  . 
4.2.  Chlorpro m a z i n e
Chlorprom azine  relieved  pain,  nausea ,  phono-  and  photophobia  in  1  h
(95%)  in  an  intravenous  dose  of  0.1  mg/kg  .  The  main  side- effects  were
postu r al  hypotension,  drowsiness  and  akathizia  . 
4.3.  Metoc l o pr a m i d e
Metoclopra mide  has  an  indication  for  the  trea tm e n t  of  nausea  and
vomiting,  and  it  may  promote  the  gast roin t es t inal  absorp tion  of  other
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medica tions,  such  as  aspirin  and  acetaminophe n  .  The  standa r d  dose  is  5
to  20  mg  for  both  oral  and  intravenous  administ r a t ion  . 
4.4.  Domp e ri d o n e
Domperidone  is  a  periphe ra l  DRD2  antagonis t ,  because  of  its  poor  blood-
brain  barrier  penet r a t ion.  In  a  20  to  30  mg  dose,  combined  adminis t ra t ion
with  1000  mg  parace t a m ol  decreas e d  the  dura tion  of  migraine  attacks  by
30%  . In  a  dose- finding  study,  domperidone  prevente d  30%  of  attacks  in  a
dose  of  20  mg,  58%  in  30  mg  and  63%  in  40  mg  .  No  side-  effects  were
published.
4.5.  Halop er id o l
Significant  migraine  pain  relief  was  observed  in  80%  of  migraineu r s  after
intravenously  adminis te r e d  haloperidol  (5  mg)  .  The  main  adverse  events
were  sedation  and  akathisia  . 
4.6.  Drop er id o l
A  randomized,  double- blind,  placebo- controlled,  dose- ranging,
multicen t r e  study  found  that   the  2  h  headach e  response  rate  was
significant  following  the  intramusc ula r  administ r a t ion  of  droperidol  in  a
dose  of  2.75  mg.  Anxiety,  akathisia  and  somnolence  were  the  main
adverse  events  .  Droperidol  is  also  contraindica t ed  in  the  event  of  a  long
QTc  interval  .
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This  D2-dopamine  recepto r  antagonis t  decreas es  only  the  premoni tory
symptoms  of  migraine ,  but  also  alleviates  the  headach e  in  combina tion
trea tm e n t s  by  ameliora t ing  the  gast ric  absorp tion.  
5.  Pitui tary  adenyla t e  cyclas e - activat in g  polyp ep t id e  type  1  (PAC1)
rece pt or
Pituita ry  adenyla te  cyclase- activating  polypeptide  (PACAP),  the  newes t
member  of  the  vasoactive  intes tinal  peptide  (VIP)/secre t in/gluca gon
neurope p tide  superfamily,  was  first  isolated  from  the  ovine  hypothalam u s
. In  humans ,  PACAP  is  encoded  by  the  ADCYAP1  gene  (propep tide  of  175
amino  acids)  and  occurs  in  two  biologically  active  forms,  the  C-terminally
trunca t e d  PACAP- 27  and  PACAP- 38  (27  or  38  amino  acids),  with  the
predomina n t  occurr enc e  of  PACAP-38  .  PACAP- 38  does  not  pass  the
blood- brain  bar rie r  as  it  is  a  large  molecule  .  The  plasma  elimination  half-
life  of  PACAP- 38  is  less  than  5  min  . 
Immunohis toche mical  studies  have  demons t r a t e d  the  expression  of
PACAP  in  the  parasymp a t h e t ic  and  sensory  ganglia  ,  the  human  TNC  and
the  C1  and  C2  levels  of  the  cervical  spinal  cord  .  PACAP  displays  a  large
variety  of  biological  effects ,  including  neuropro te c t ion,  stimula tion  of  cell
prolifera t ion  and  differen tia t ion,  and  an  anti- apoptot ic  effect  .
In  recen t  years,  numerous  data  have  been  published  on  the  role  of  PACAP
in  pain  transmission  and  the  pathomec h a ni s m  of  primary  headache s  .
Preclinical  experimen t a l  studies  sugges t e d  the  crucial  role  of  PACAP- 38
in  TS  activation  .  Stimula tion  of  the  superior  sagitt al  sinus,  which  is
densely  innervat e d  by  the  periphe r a l  branch  of  the  perykarya  of  the
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TRIG,  resul ted  in  an  increase d  level  of  PACAP  in  the  cranial  outflow  . One
of  the  main  concomitan t  featu re s  of  a  migraine  attack  is  photophobia.  A
reduced  level  of  light- aversive  behavior  has  been  demonst r a t e d  in  PACAP
gene- deleted  mice  after  nitroglycerin  (NTG)  administ r a t ion,  and  PACAP-
38  elicited  light- aversion  in  wild- type  mice  .  During  elect rical  TRIG
stimulation  in  rats,  an  increase d  plasma  level  and  TNC  concen t r a t ion  of
PACAP- 38  were  observed  .
Schytz  et  al.  demonst r a t e d  that  the  intravenous  adminis t r a t ion  of  PACAP-
38  resulted  in  headache  in  healthy  subjects ,  and  in  migraine- like
headach e  in  migraineu r s  without  aura  4-5  h  after  the  infusion,  increasing
the  diamete r  of  the  superficial  temporal  arte r ies  and  decreasing  the  mean
blood  flow  velocity  of  the  middle  meningeal  arte ries  .  PACAP- 38  infusion
caused  the  pronounce d  dilata t ion  of  the  extrac r a nial ,  but  not  the
intrac r a nia l  arte ries  .  It  was  interes t ing  that  anothe r  member  of  this
neurope p tide  superfamily,  VIP,  did  not  induce  migraine  headach e  on
intravenous  administ r a t ion   and  the  VIP-induced  dilation  was  normalized
in  a  shorte r  period  relative  to  PACAP- 38  induced  vasodilation  .  In  an  in
vivo  human  study,  the  plasma  concen t r a t ion  of  PACAP- 38  proved  to  be
significantly  lower  in  the  interictal  period  in  migraineu r s  as  compare d
with  heal thy  individuals,  and  increas ed  significantly  during  the  ictal
period  . 
These  findings  open  the  way  for  furthe r  resea r ch  to  identify  specific
cause- related  therapy.
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The  effects  of  PACAP  are  mediat ed  through  the  class  B  family  of  7-
transm e m b r a n e  GPCRs,  i.e.  VPAC1,  VPAC2  and  PAC1  .  PACAP  is  1000-
fold  more  potent  than  VIP  at  the  PAC1  recep to r  ,  while  VIP  and  PACAP
bind  to  the  VPAC1  and  VPAC2  recepto rs  with  equal  affinity  . As a  result  of
the  activation  of  PACAP  recep to rs ,  increase s  in  the  levels  of  cAMP,
phospholipase  C  and  intracellula r  calcium  were  observed  .  In  view  of  the
differen t  PACAP  and  VIP  recepto r  kinetics  and  the  human  observa t ions
that  PACAP  did,  but  VIP  did  not  induce  a  migraine  attack,  the  PAC1
recepto r  may  be  a  future  candida t e  as  a  therape u t ic  targe t .  Until  now
only  one  PAC1  recepto r  agonis t  (maxadilan)  is  available,  which  was
isolated  from  salivary  glands  of  the  sand  fly  Lutzo myia  longipalpis .  It  is  a
61- amino  acid  peptide.  For  its  activity  the  integri ty  of  the  ring  between
14  and  51  is  necessa ry.  On  the  other  hand  the  deletion  of  the  amino  acids
between  25  and  41  genera t e d  a  specific  PAC1  recepto r  antagonis t ,
termed  M65  .  A  recen t  study  proved  that  maxadilan  had  no  effect  on
CGRP  release  and  M65  did  not  block  the  PACAP- 38- induced  CGRP
release  in  the  TS  . An  additional  task  for  drug  developme n t  procedu re s  is
to  creat e  a  PAC1  recepto r  blocker  which  can  cross  the  blood- brain  bar rie r
to  reach  the  possible  migraine  related  structu r e s .
6.  N- Methyl- D- asparta t e  (NMDA)  recep t or s
Glutama t e  is  the  main  excita tory  amino  acid  in  the  mammalian  central
nervous  system.  Both  experimen t a l  and  human  studies  have  indicated  the
role  of  glutama t e  in  the  pathogen e si s  of  migraine  .  Animal  studies
revealed  the  presenc e  of  glutam a t e r g ic  neurons  in  the  TRIG  ,  and  dural
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and  trigeminal  nerve  stimula tion  increas ed  the  level  of  glutam a t e  in  the
TNC  .  In  human  studies,  an  elevated  level  of  glutama t e  was  observed  in
the  cereb ros pinal  fluid  , the  plasma   and  the  saliva   in  migraine  patien t s .  
The  glutama t e- induced  excitability  is  media ted  via  ionotropic  (iGluRs)  and
metabot ropic  glutam a t e  recepto rs .  The  iGluRs  are  glutama t e- gated  ion
channels  that  media te  fast  synaptic  transmission.  They  are  subdivided
into  three  subtypes:  NMDA,  -amino- 3-hydroxy- 5-methyl- 4-α
isoazolepropionic  acid  (AMPA)  and  kainat e  .  NMDA  recepto rs  form
tetra m e r ic  assemblies  of  seven  subuni ts ,  NR1,  NR2A- D  and  NR3A- B.  For
the  activation  of  NMDA  recepto r s ,  the  binding  of  glutama t e  and  a  co-
agonist  glycine  or  D-serine  is  needed  .  The  NMDA  recepto r  protein
complex  contains  a  binding  site  within  the  channel  pore  for  Mg 2+ ;  it  is
permea ble  to  Na + ,  K+  and  Ca 2+  and  sites  of  action  for  polyamines ,  zinc
and  protons  are  also  found  in  the  NR2  subunit  .  NMDA  recep to rs  are
expresse d  in  the  superficial  laminae  of  the  TNC  in  rat  ,  in  the  TRIG   and
in  the  thalamus  , and  they  are  also  involved  in  central  sensitiza tion  . 
Cortical  spreading  depre ss ion  (CSD)  is  a  propaga ting  transien t  nega tive
direc t  potential  shift,  which  occurs  in  migraine  with  aura  .  Elevation  of
the  extracellula r  concen t r a t ion  of  K+  is  a  poten t  trigger  of  CSD  .  The
inhibition  of  this  process  by  NMDA  recepto r  antagonis t s  emphasizes  the
action  of  glutam a t e  in  the  initiation  of  CSD  .
The  possible  effects  of  NMDA  recepto r  antagonis t s  have  been  examined
in  animal  models  and  clinical  trials.
6.1.  MK- 801
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MK-801,  a  non- competi t ive  NMDA  recep to r  channel  blocker,  has  been
found  to  reduce  Fos- like  immunore a c t ivity  and  decreas e  the  increas e d
local  blood  flow  in  the  cat  trigeminoce rvical  complex  after  stimula tion  of
the  superior  sagit tal  sinus  ,  to  inhibit  CSD  ,  and  to  decreas e  the
neuroge nic  dural  vasodila tion  ,  but  to  increas e  the  neuronal  activity  in
the  descending  anti- nociceptive  system  (the  ventrola t e r a l  periaqued uc t a l
grey  mat te r  (PAG),  nucleus  raphe  magnus  (NRM),  dorsal  raphe  nucleus
and  Edinge r- Westphal  nucleus)  .  During  spontaneous  migraine  attacks,
an  increas ed  blood  flow  of  specific  brains te m  nuclei,  such  as  the  NRM,
PAG  locus  coeruleus  (LC)  ("migraine  genera to r s")  was  observed  by  high-
resolution  positron  emission  tomograp hy  .  Human  immunohis toche mical
studies  revealed  CGRP,  PACAP  immunore a c t ive  fibres  and  neurons  in  the
LC,  and  substance  P  afferen ta t ion  in  the  PAG  and  RNM  .  These
observa t ions  sugges t ed  that  these  specific  nuclei  influence  the  activation
of  TNC.  Human  Phase  I studies  are  required .
6.2.  Mema n t i n
Meman tin  is  another  non- competi t ive  NMDA  recep to r  blocker ,  with  an
effect  of  CSD  preven tion  . In  a  clinical  study,  meman tin  in  a  dose  of  10  to
20  mg  was  effective  as  preventive  trea tm e n t  of  refrac to ry  migraine,  as  it
significantly  decreas e d  the  monthly  headache  frequency  and  the  mean
disability  score  .  On  the  other  hand,  37.5%  of  the  patient s  repor t ed  side-
effects ,  such  as  somnolence ,  asthenia ,  anxiety,  depression  and  an
increas e  in  weight  .
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6.3.  L-701 , 3 2 4
L-701,324  is  an  NMDA  glycine- site  antagonis t .  On  systemic
adminis t ra t ion  it  inhibited  CSD  in  rats  .
6.4.  Keta mi n e
Ketamine,  a  non- competi t ive  NMDA  recep to r  antagonis t ,  reduced
neuroge nic  dural  vasodila tion  in  an  experimen t a l  model  .  In  a  very  small
human  study  (n=11)  designed  to  examine  the  effect  of  intranas a lly
adminis te r e d  (25  mg)  ketamine  in  migraineu r s  with  familial  hemiplegic
migraine ,  5  patient s  manifes ted  beneficial  effects .  It  reduced  the  severi ty
and  dura tion  of  the  aura  symptoms  .
6.5.  Kynure n i n e s
Recent  preclinical  experimen t a l  data  sugges t ed  a  connec tion  between  the
kynurenines  and  the  pathomec h a ni s m  of  migraine  .  The  tryptopha n
metabolism  has  two  major  pathways:  the  well- known  5-HT  pathway,  and
the  lesser- known  L-kynurenine  (L-KYN)  pathw ay,  which  also  has  an
import an t  impact ,  as  kynurenic  acid  (KYNA)  is  one  of  the  very  few
endogenous  NMDA  recepto r  antagonis t s  .  Its  40%  is  produced  locally  in
the  centr al  nervous  system,  while  the  remaining  60%  is  taken  up  from  the
blood  .  KYNA  (4-hydroxyquinoline- 2-carboxylic  acid)  is  produced  from  L-
KYN  by  neurons  and  astrocytes  .  At  7.9  M,  KYNA  effectively  inhibitedμ
the  NMDA  recepto r s  via  attachm e n t  to  the  glycine- binding  site  .  It  is  to
be  noted  that  KYNA  has  a  concen t r a t ion- depende n t  neuromodula to ry
effect,  like  a  Janus- face  compound.  In  a  nanomolar  concen t r a t ion  it
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facilita tes ,  while  in  a  micromolar  concen t r a t ion  it  inhibits  the  NMDA  and
AMPA  recep to r s  .  In  an  animal  migraine  model  chemically  induced  by
NTG,  c-fos  and  calmodulin- depende n t  protein  kinase  II  alpha  activation
occur re d  in  the  second- order  nocicep tive  neurons,  an  effect  which  was
inhibited  by  the  KYNA  precursor  L-KYN  .  Concerning  the  blood- brain
barrie r  penet r a t ion  only  the  L-tryptopha n ,  L-KYN  and  3-hydroxy- l-
kynurenine  can  be  transpor t e d ,  while  KYNA  can  poorly  penet r a t e .  The
halogena t e d  derivative  4-chlorokynure nine  can  be  transpor t ed  through
the  blood- brain  barrier  as  L-KYN,  and  therefore  causing  the  release  of  7-
chlorokynure nic  acid  from  astrocytes  .
As  an  endogenous  NMDA  recep to r  antagonis t ,  KYNA  influences  pain
transmission  via  second- order  neurons  in  the  TNC  and  can  modula te
pain- control  through  the  brains te m  "migraine  genera to r s".  Good  blood-
brain  bar rie r- penet r a t ing  synthe t ic  KYNA  analogues  are  needed  for  a
human  Phase  I study.
7.  Conclu s i o n s
Migraine  afflicts  16%  of  the  genera l  popula tion  world- wide,  but  the  exact
pathomec h a ni s m  and  cause- related  attack  therapy  are  still  unsolved.  The
leading  hypothesis  postula t es  that   CGRP  is  a  migraine- related
neurope p tide .  The  functional  CGRP  recep to r  has  been  described  and  its
antagonis t s  have  been  developed.  They  have  beneficial  effects  on
migraine  headache ,  without  side- effects  of  coronary  const ric t ion  such  as
those  of  triptans .  The  disadvan t a g e  of  these  pharm acons  is  the  related
liver  toxicity,  which  prevent s  their  wide- spread  clinical  use.  The  5-HT-1F
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recepto r  agonis t  lasmiditan  is  a  neurally  acting  anti- migraine  agent  which
proved  effective  in  clinical  studies ,  but  the  severe  adverse  centra l
nervous  system- related  events  limit  its  usage.  Another  possible  targe t  is
the  D2- dopamine  recepto r ;  its  antagonis t s  in  a  single  therapy  influenced
only  the  premoni tory  symptoms  of  migraine ,  and  not  headach e  pain.
Nowadays  the  preclinical  data  indicate  that  the  PAC1  recepto r  is  a  targe t
for  new  therape u t ic  options  for  migraine.  Recent  experime n t a l  studies
demons t r a t e d  that  the  excita tory  recepto rs  takes  par t  in  the  activation  of
the  TS,  and  its  antagonis t s  are  promising  future  therap eu t ic  candida t e s .
8.  Expert  Opinion
Migraine  is  a  very  devasta t ing  neurovascula r  disorder  accompa nied  by
severe  headach e  pain  and  concomitan t  clinical  conditions  such  as  photo-
and  phonophobia,  nausea ,  vomiting,  vertigo,  and  cephalic  and
extracep h a lic  allodynia.  Both  patien ts  and  neurologis ts  seek  the
attainm en t  of  rapid  and  complet e  relief  from  pain  and  the  associa ted
symptoms  with  safety,  good  tolerabili ty  and  a  low  side- effect  profile,  with
simple  adminis t ra t ion  and  low  price.  Medication  with  a  good
pharm acokine t ic  profile  can  fulfil  these  expecta t ions .
During  the  past  15  years,  the  gold  standa r d  of  acute  migraine  therapy  has
been  based  on  the  use  of  triptans ,  highly  selective  5-HT1B/1D  recepto r
agonist s  that  cause  vasocons t r ic t ion  via  the  5-HT1B  recep to rs  and  inhibit
neurope p tide  (e.  g.  CGRP)  release  from  the  trigeminal  nerve  endings .
They  can  diminish  headach e  pain  with  high  efficacy.  They  are  available
for  differen t  adminis t r a t ion  routes  as  tablets ,  orally  disinteg ra t ing  table ts ,
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intrana s al  sprays,  rectal  supposi tories  and  subcutan eo us  injections ,
which  are  favoured  by  the  patient s .  The  problem  is  that  they  do  not  cover
the  overall  popula tion  of  migraineu r s  and  the  related  coronary
vasocons t r ic tion.  To  avoid  vasocons t r ic t ion,  and  to  diminish  CGRP-
induced  TS  activation,  CGRP- RAs  ("gepan t s")  have  been  developed.  The
first  was  olcegepan t ,  which  proved  very  efficacious  in  alleviating  the  pain,
but  its  disadvan t a g e  was  the  intravenous  adminis t ra t ion  route,  which
prevente d  its  wide- spread  clinical  use.  A  new  type  of  CGRP- RAs,
telcagepa n t ,  was  synthet ized  for  oral  adminis t ra t ion.  The  Phase  II  proof-
of-concep t  study  demonst r a t e d  its   effectivity  versus  placebo  and  the
comparison  with  triptan  (zolmit rip tan)  revealed  a  similar  effect.  The
problem  with  this  drug  was  the  liver  toxicity  (elevated  liver  transa minas e)
on  long- term  and  frequen t  use.  The  task  for  future  pharm ac e u t ical
resea rc h  is  to  develop  a  CGRP- RA without  liver  toxicity.  
Another  way  to  avoid  the  5-HT1B  recep to r- media ted  direc t
vasocons t r ic to r  effect  is  the  synthesis  of  5-HT1F  recep to r  agonis ts ,  as
neurally  acting  anti- migraine  agents .  The  recen tly  developed  highly
selective  5-HT1F  recepto r  agonis t  lasmiditan  was  superior  to  placebo  in
diminishing  the  headache ,  but  its  severe  central  nervous  system- related
side- effects ,  such  as   dizziness,  fatigue,  vertigo  and  paraes t he s i a ,  limit  its
use.
Migraineu r s  are  hypers ensi t ive  to  dopamine  and  in  migraineu r s  without
aura  the  polymorphism  of  DRD2  encoding  gene  has  been  observed.  Well-
known  DRD2  antagonis t s  tested  in  migraine  attacks ,  mitigated  only  the
premoni tory  symptoms.  It  should  be  highlighted  that  these  drugs
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combined  with  aspirin,  acetaminophe n  or  parace t a m ol  alleviated  the
headach e  by  ameloria ting  the  gast ric  absorp tion.  
Numerous  data  have  been  published  on  the  role  of  PACAP  in  pain
transmission  and  the  pathomec h a ni s m  of  primary  headache s .  In  contras t
with  VIP,  which  is  also  a  member  of  the  secre tin/glucagon  neuropep t ide
superfamily  and  a  well- known  vasodila tor ,  only  PACAP- 38  induced
migraine  headache  after  intravenous  adminis t ra t ion.  This  featu re  of
PACAP- 38  was  similar  to  that  of  intravenously  adminis te r e d  alpha- CGRP.
Moreover ,  during  a  spontaneous  migraine  attack  the  plasma  level  of
PACAP- 38  is  significan tly  elevated  as  compare d  with  the  headache- free
period,  as  for  CGRP  during  the  attack  in  the  cranial  outflow.
Immunohis toche mical  studies  have   revealed  that  CGRP  and  PACAP- 38
are  located  in  the  trigeminal  pseudounipola r  neurons.  It  is  possible  that
they  have  a  common  role  in  activating  the  TS.  PACAP  and  VIP  have
common  recepto rs ,  VPAC1  and  VPAC2,  while  the  PAC1  recep to r  is
specific  for  PACAP.  Analogously  to  the  CGRP- RAs,  PAC1  recep to r
antagonis t s  should  be  developed,  with  a  capability  of  blood- brain  barrie r
pene t r a t ion .
One  of  the  recepto r s  of  the  main  excitato ry  amino  acid,  glutam a t e ,  is  the
NMDA  recep to r .  Glutama t e  has  a  crucial  role  in  TS  activation.  Synthe tic
NMDA  recepto r  channel  blockers  have  been  tested  in  par t  in  human
studies,  but  need  to  reach  the  Phase  I  study  level.  The  recent  preclinical
experimen t a l  data  sugges t e d  a  connection  between  the  kynurenines  and
TS  activation.  KYNA  is  one  of  the  very  few  endogenous  NMDA  recepto r
antagonis t s .  The  drawback  of  this  substanc e  is  its  very  poor  blood- brain
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barrie r  penet r a t ion .  In  order  to  organize  a  proof- of-concept  human  study,
the  developme n t  of  good  blood- brain  bar rie r-  pene t r a t ing  synthet ic
analogues  is  required .  
Each  of  the  above- mentioned  molecules  have  beneficial  charac t e r i s t ics,
but  more  developme n t  and  Phase  studies  are  needed  for  their  final
evalua tion.
Highl i g h t s
- The  pathom ec h a n is m  of  migraine  and  the  therapy  of  migraine  attacks  
are  still  unsolved.
- Calcitonin  gene- related  peptide  recepto r  antagonis t s  are  effective  
without  the  side- effect  of  corona ry  const ruc t ion,  but  the  related  liver  
toxicity  prevent s  their  wide- spread  clinical  use.
- The  5-hydroxytrypta mine  1F  recep to r  agonis t  is  effective  as  a  neurally  
acting  anti- migraine  agent ,  but  the  severe  adverse  central  nervous  
system- related  events  limit  its  clinical  use.
- The  D2-dopamine  recepto r  antagonis t s  alone,  merely  influence  the  
premoni tory  symptoms  of  migraine,  and  not  the  pain.
- The  pituita ry  adenyla te  cyclase- activating  polypep tide  type  1  recep to r  
blocker  is  a  future  candida t e  for  migraine  therapy,  but  its  blood- brain  
bar rie r  penet r a t ion  is  poor.
- N -Methyl- D-aspar t a t e  recepto r  antagonis t s  are  promising  
experimen t a lly,  but  Phase  I studies  are  necessa ry.
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Table
Table  1  Distribu tion  of  recep to r s  in  migraine  related  struc tu r e s  and  
recepto r- binding  compounds  for  migraine  trea tm e n t
Recep t or Migrain e  relat e d  
struc t ur e s
Recep t or  
agoni s t
Recep t or  
antag o n i s t
CGRP Trigeminal  ganglion
Trigeminal  nucleus  
caudalis
Sphenopala t ine  
ganglion
Cerebr al  dura  mate r
Cerebella r  cortex
Olcegepa n t
Telcagepa n t
5-HT1F Trigeminal  ganglion
Trigeminal  nucleus  
caudalis













PAC1 Trigeminal  ganglion
Trigeminal  nucleus  
caudalis






NMDA Trigeminal  ganglion







Kynurena t e  
derivative
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Figur e  lege n d
Figur e  1  Scheme  of  the  trigeminovascula r  system  (TS).
The  periphe ra l  branch  of  the  pseudounipola r  neurons  in  the  trigeminal  
ganglion  (TRIG)  innerva t es  the  vessel  wall  of  the  pial  and  dural  
vascula tu r e ,  and  the  central  nerve  ending  synapse  in  the  second- order  
neurons  in  the  trigeminal  nucleus  caudalis  (TNC).  During  activation  of  
the  TS,  as  in  a  migraine  attack,  calcitonin  gene- related  peptide  (CGRP),  
glutama t e  and  pituita ry  adenyla te  cyclase- activating  polypep tide  (PACAP)
are  release d  from  the  periphe r a l  and  the  centra l  arch  of  the  trigeminal  
neurons,  which  causes  periphe r a l  and  central  sensitiza tion.
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